AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 09:05:21 17/07/2024 pm IST			5-day change	1st Jan Change
12,244 ^GBX	+1.19%		+1.37%	+15.51%

05:31pm	AstraZeneca's Capivasertib Gets UK Marketing Authorization for Advanced Breast Cancer Treatment	MT
10:20am	EU court criticizes Commission over handling of COVID vaccine contracts	RE

ASTRAZENECA : Gets a Neutral rating from Deutsche Bank

January 30, 2024 at 05:33 pm IST

Initially Neutral on the company, Deutsche Bank's analyst Emmanuel Papadakis maintained his recommendation. The target price remains set at GBX 11000.

Latest news about AstraZeneca PLC

AstraZeneca's Capivasertib Gets UK Marketing Authorization for Advanced Breast Cancer Treatment	09:01pm	MT
EU court criticizes Commission over handling of COVID vaccine contracts	01:50pm	RE
Global markets live: Airbus, Burberry, AT&T, Boeing, Vinfast...	15/07
AstraZeneca: acquisition of Amolyt Pharma finalized	15/07	CF
AstraZeneca Closes $1.05 Billion Amolyt Pharma Acquisition	15/07	MT
AstraZeneca PLC completed the acquisition of Amolyt Pharma SAS for $1.05 billion.	15/07	CI
Instil Bio Shares Surge Following Rental Agreement with AstraZeneca	13/07	DJ
Sector Update: Health Care Stocks Mixed Premarket Friday	12/07	MT
Instil Bio Signs Lease With AstraZeneca Pharmaceuticals at California Facility; Shares Rise After Hours	12/07	MT
ASTRAZENECA : Deutsche Bank reiterates its Neutral rating	10/07	ZD
Barclays raises Kerry, cuts Hunting, Wood Group	10/07	AN
ASTRAZENECA : JP Morgan reaffirms its Buy rating	10/07	ZD
AstraZeneca's Tagrisso Approved by EU as First-Line Treatment for Non-Small Cell Lung Cancer	05/07	MT
AstraZeneca: cancer treatment approved by the EU	05/07	CF
AstraZeneca drug Tagrisso gets EU approval for cancer form	05/07	AN
EU Approves AstraZeneca's Tagrisso Combo as Non-small Cell Lung Cancer Treatment	05/07	MT
ASTRAZENECA : Goldman Sachs maintains a Buy rating	04/07	ZD
ASTRAZENECA : Buy rating from Berenberg	03/07	ZD
Aptamer shares jump as inks agreement with AstraZeneca	03/07	AN
Aptamer Group plc Announces New Agreement with AstraZeneca to Evaluate the Optimer Fibrotic Liver Delivery Vehicles for the Targeted Delivery of SiRNA	03/07	CI
ASTRAZENECA : Jefferies reaffirms its Neutral rating	02/07	ZD
Deutsche Bank cuts Quilter, ups Polar Capital	02/07	AN
European Equities Close Higher in Monday Trading; Eurozone Manufacturing Contraction Widens in June	01/07	MT
UK Stocks Flat; Manufacturing Sector Remains in Expansion Zone	01/07	MT
AstraZeneca's Potential Covid-19 Prevention Drug Gets EU Accelerated Assessment	01/07	MT

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

25/07/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 09:32 pm IST

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

156.8 USD

Average target price

177.6 USD

Spread / Average Target

+13.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+15.51%	24TCr
ELI LILLY AND COMPANY	+56.20%	85TCr
NOVO NORDISK A/S	+31.64%	63TCr
JOHNSON & JOHNSON	-0.18%	36TCr
MERCK & CO., INC.	+15.32%	32TCr
ABBVIE INC.	+12.99%	30TCr
NOVARTIS AG	+16.72%	23TCr
AMGEN INC.	+16.21%	18TCr
PFIZER, INC.	+3.96%	17TCr
SANOFI	+2.52%	13TCr

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

ASTRAZENECA : Gets a Neutral rating from Deutsche Bank

Latest news about AstraZeneca PLC

Chart AstraZeneca PLC

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for AstraZeneca PLC

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals